Please login to the form below

Not currently logged in
Email:
Password:

brivaracetam

This page shows the latest brivaracetam news and features for those working in and with pharma, biotech and healthcare.

UCB’s antiepileptic drug gains new US indication

UCB’s antiepileptic drug gains new US indication

FDA approves Briviact as a monotherapy to treat POS. The US Food and Drug Administration (FDA) has approved UCB’s Briviact (brivaracetam) CV as a monotherapy treatment option for epilepsy patients

Latest news

  • SMC gives green light for BMS’ Opdivo SMC gives green light for BMS’ Opdivo

    2014. Additionally, the SMC gave three further approvals to Lundbeck's antidepressant Brintellix (vortioxetine), Novartis' Cosentyx (secukinumab) for ankylosing spondylitis, and UCB's Briviact (brivaracetam) for partial-onset seizures in epilepsy

  • UCB bags FDA approval for epilepsy drug Briviact UCB bags FDA approval for epilepsy drug Briviact

    The US regulator has given the go-ahead to Briviact (brivaracetam) as an add-on treatment to other medications to treat partial onset seizures in patients aged 16 years and older ... Unlike many current epilepsy drugs, brivaracetam does not require dose

  • UCB wins European approval for epilepsy drug Briviact UCB wins European approval for epilepsy drug Briviact

    In trials, brivaracetam significantly reduced the frequency of seizures compared to placebo, with a 50% reduction in seizures seen in up to 40% of patients treated with UCB's drug. ... Unlike many current epilepsy treatments brivaracetam does not require

  • UCB boosted by core medicines growth UCB boosted by core medicines growth

    romosozumab for osteoporosis, lupus treatment epratuzumab, and brivaracetam for epilepsy. .

  • UCB submits brivaracetam for use in epilepsy UCB submits brivaracetam for use in epilepsy

    Files drug in both the US and EU. Belgian pharma company UCB has filed its investigational drug brivaracetam for approval to treat epilepsy in both the US and EU. ... A fourth phase III study evaluated the safety and tolerability of adjunctive

More from news
Approximately 3 fully matching, plus 8 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Havas Lynx Group

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics